LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Mobile Kidney Disease Testing Device Measures Urine Albumin at POC

By LabMedica International staff writers
Posted on 06 Jul 2022
Print article
Image: A new portable medical device can monitor and enable early detection of CKD (Photo courtesy of Flinders University)
Image: A new portable medical device can monitor and enable early detection of CKD (Photo courtesy of Flinders University)

A new portable medical device for monitoring and early detection of chronic kidney disease (CKD), which affects an estimated 9% of the world’s population, has been shown to have potential to service rural and remote patients and communities with limited medical services. The affordable device can accurately measure levels of albumin in patients’ urine. Elevated albuminuria levels indicate an individual’s kidneys are not filtering blood proteins effectively.

The 3D printed medical device was designed, constructed and evaluated by researchers at Flinders University (Adelaide, Australia) and accurately measures concentrations of albumin in urine samples via an advanced specified aggregation induced emission (AIE) biosensor. In a proof-of-concept study, the platform was able to detect urinary albumin with high accuracy and low cost, making it a potential device for detecting and monitoring albuminuria levels for kidney disease.

The device is also adaptable for potential monitoring of cancers, amyloid fibrils, and other disease biomarkers. The system requires a digital camera, embedded printed circuit boards, single light source and access to the software and can be operated by anyone without the need for a clinical setting or expert diagnostic laboratory.

“A reliable, portable device to accurately measure urine albumin could be rolled out to point-of-care testing sites in the community to reduce the need for patients with chronic kidney disease to regularly visit a hospital or clinic,” said co-author Professor Karen Reynolds, Director of Flinders University’s Medical Device Research Institute and Joint Research Centre for Personal Health Technologies at Tonsley Innovation District. “It will also help early detection of kidney disease which is imperative for early intervention to slow its progression.”

Related Links:
Flinders University

Gold Member
Flocked Fiber Swabs
Puritan® Patented HydraFlock®
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Silver Member
Total Hemoglobin Monitoring System
GREENCARE Hb
New
Respiratory QC Panel
Assayed Respiratory Control Panel

Print article

Channels

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Microbiology

view channel
Image: The lab-in-tube assay could improve TB diagnoses in rural or resource-limited areas (Photo courtesy of Kenny Lass/Tulane University)

Handheld Device Delivers Low-Cost TB Results in Less Than One Hour

Tuberculosis (TB) remains the deadliest infectious disease globally, affecting an estimated 10 million people annually. In 2021, about 4.2 million TB cases went undiagnosed or unreported, mainly due to... Read more

Pathology

view channel
Image: The UV absorbance spectrometer being used to measure the absorbance spectra of cell culture samples (Photo courtesy of SMART CAMP)

Novel UV and Machine Learning-Aided Method Detects Microbial Contamination in Cell Cultures

Cell therapy holds great potential in treating diseases such as cancers, inflammatory conditions, and chronic degenerative disorders by manipulating or replacing cells to restore function or combat disease.... Read more

Technology

view channel
Image: The HIV-1 self-testing chip will be capable of selectively detecting HIV in whole blood samples (Photo courtesy of Shutterstock)

Disposable Microchip Technology Could Selectively Detect HIV in Whole Blood Samples

As of the end of 2023, approximately 40 million people globally were living with HIV, and around 630,000 individuals died from AIDS-related illnesses that same year. Despite a substantial decline in deaths... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Sekisui Diagnostics UK Ltd.